Key result
Structural modeling indicates that GS-441524 addresses both RdRp and ExoN active sites, consistent with significant incorporation, delayed chain termination, and altered excision.
Why the study?
The rapid emergence of SARS-CoV-2 created an immediate need for antivirals, but coronaviruses present challenges for nucleoside analogue design due to an exonuclease capable of excising incorporated analogues.
Structural modeling suggests that the active metabolite of remdesivir (GS-441524) evades viral exonuclease activity due to its ribose 1'-CN group, explaining its antiviral efficacy against SARS-CoV-2.
Answers are grounded in this paper and cite their sources.
May guide nucleoside analog optimization against proofreading viruses; leaves open clinical translation in SARS-CoV-2.
The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation. To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogues (NAs), with over 25 approved for the treatment of several medically important viral diseases. However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals. Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes. We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision. Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogues. Additionally, we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir. This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN.
No takes yet. Share an insight, caveat, or question.
Shannon et al. (2020) studied SARS-CoV-2. GS-441524 (Remdesivir active metabolite) was evaluated on Structural modeling of nucleotide recognition, discrimination, and excision. Structural modeling indicates that GS-441524 addresses both RdRp and ExoN active sites, consistent with significant incorporation, delayed chain termination, and altered excision.
Synapse has enriched 10 related papers. Consider them for comparative context: